Body Fluid Sample Diluent Using Mediators to Limit Glycation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The glycation degree of proteins in body fluid samples, such as glycoalbumin, changes during transport or storage due to reactions with glucose, especially in high-temperature environments, leading to inaccurate assay results.
Innovation Solution
A solution containing kanamycin, G418, streptomycin, maltotriose, or N-acetylmuramic acid is used to dilute the body fluid sample, reducing the frequency of glycation reactions and maintaining assay accuracy by stabilizing the glycation degree.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If the body fluid sample is transported or stored without temperature control, then the transport cost is reduced, but the glycation degree of proteins changes due to high-temperature reactions with glucose
Solution Approach 1:
The patent introduces an intermediary substance (aminoglycoside antibiotic or saccharide) that mediates between the glucose and protein, preventing the direct glycation reaction. The antibiotic binds to glucose or competes for binding sites, while the saccharide acts as a competitive substrate, thereby stabilizing the glycation degree during transport without requiring temperature control
Solution Approach 2:
The patent changes the chemical composition parameters of the sample by adding specific substances (aminoglycoside antibiotics like kanamycin or saccharides like maltotriose) that alter the reaction kinetics between glucose and protein. This parameter change prevents glycation progression at ambient temperatures, allowing cost-effective transport without refrigeration
2Reliability
If the dilution factor is increased to reduce glycation increase, then the assay values are stabilized, but the concentration of analyte decreases
Solution Approach 1:
The patent optimizes the dilution factor parameter to a specific range (5-20 times dilution) that balances two competing requirements: reducing the rate of glycation reactions while maintaining sufficient analyte concentration for accurate measurement. This parameter optimization allows moderate dilution without sacrificing assay sensitivity
3Stability of the object's composition
If the body fluid sample is diluted to reduce glycation reactions, then the glycation degree stability is improved, but the sample volume required increases
Solution Approach 1:
The patent uses an intermediary substance that can be added in small volumes to achieve glycation inhibition without requiring large dilution volumes. The antibiotic or saccharide acts as a potent inhibitor at low concentrations, providing stability with minimal volume increase
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution effectively maintains the glycation degree of proteins within acceptable limits, ensuring accurate assay results even in high-temperature conditions without temperature control, thus enabling cost-effective transport testing.
Implementation Method 1
glucose and other components react with proteins such as albumin, and the proteins may become degraded
Implementation Method 2
increasing the dilution factor can reduce the increase in glycation degree and thus can substantially eliminate the influence on the assay values
Data Source
Figure 1
Figure 2
Figure 3
AI summary
An aspect of the present disclosure provides a solution for transporting or storing a body fluid sample, the solution including a substance selected from the group consisting of kanamycin, G418, streptomycin, maltotriose, N-acetylmuramic acid, and glucose as an active ingredient.